Topical medication

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 

Retrieved on: 
星期三, 四月 17, 2024
University, Radiation, BC Cancer Agency, Mouse, Cell, Carcinoma, Skin, Aks, UVB, Topical medication, University of British Columbia, IND, Patient, BC Cancer Research Centre, Neoplasm, Toxicity, Medication, Pharmaceutical industry

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world.

Key Points: 
  • VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world.
  • Treating AKs before the cells become cancerous and spread to other parts of the body is crucial.
  • For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy.
  • There is a real need for safer and more targeted topical therapies.”
    Derm-Biome expects to start topical formulation development this summer, with IND-enabling studies slated to begin in Q4.

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Retrieved on: 
星期二, 二月 27, 2024
Vitiligo, Therapy, BET, Topical medication, Pharmaceutical industry

Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201

Key Points: 
  • Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201
    BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentation featuring positive data from the Phase 1b trial of VYN201 in vitiligo at the 2024 Global Vitiligo Foundation Annual Scientific Symposium taking place in San Diego on March 7, 2024.
  • “We are pleased to have this opportunity to present the data from our Phase 1b trial with the vitiligo community at the Global Vitiligo Foundation Annual Scientific Symposium,” said Dr. Iain Stuart, Chief Scientific Officer of VYNE.
  • “The positive clinical data from the Phase 1b trial supports the advancement of VYN201 into a Phase 2b trial that we expect to initiate next quarter.”
    A Phase 1 Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of a Topical Pan-BD BET Inhibitor (VYN201) in Subjects with Active Non-Segmental Vitiligo (session #4)

Boudreaux's® Butt Barrier® Ointment Awarded 2024 Product of the Year

Retrieved on: 
星期五, 二月 9, 2024
Trust, Pediatrics, Skin, Associate, Irritation, Safety, Topical medication, Kantar, Parent, Prestige Consumer Healthcare, Butt, Dermatitis, Petroleum jelly

TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar. The Product of the Year USA Award is one of the most respected honors in the consumer goods industry, celebrating excellence in product innovation and quality. Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability.

Key Points: 
  • TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar.
  • Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability.
  • Developed with the utmost care and expertise by Boudreaux's Butt Paste's team of experts, Boudreaux's Butt Barrier® Ointment offers a unique blend of ingredients designed to create a protective barrier against wetness and irritation.
  • The Butt Barrier® Ointment is clinically tested, hypoallergenic, fragrance free and has been accepted by the National Eczema Association.

Eirion Therapeutics to Present at the 2024 IMCAS WORLD CONGRESS

Retrieved on: 
星期五, 二月 2, 2024
World Congress, MD, Dermatology, Congress, Therapy, Topical medication

WOBURN, Mass., Feb. 2, 2024 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will be participating in the 2024 International Master Course on Aging Science (IMCAS) World Congress, taking place February 1 – 3, 2024, in Paris.

Key Points: 
  • WOBURN, Mass., Feb. 2, 2024 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will be participating in the 2024 International Master Course on Aging Science (IMCAS) World Congress, taking place February 1 – 3, 2024, in Paris.
  • "IMCAS is one of the premiere aesthetic conferences in the world, and I am excited to showcase Eirion's botulinum product candidates and pipeline progress to my global industry colleagues," commented Dr. Edelson.
  • IMCAS congresses are medical research conferences focused on providing plastic surgeons and dermatologists with the latest academic and industry updates for their professional progress in the aesthetic field.
  • IMCAS Paris kicks off the IMCAS congress schedule for the year.

SEC Office of the Investor Advocate Publishes Its Policy Recommendations on Mandatory Arbitration and Registered Index-Linked Annuities Research

Retrieved on: 
星期二, 十二月 5, 2023
Policy, Comprehension, Topical medication, Metric, Fiscal, Congress, Office, Human, Empirical research, Commission, Security (finance), Financial adviser

Washington, D.C.--(Newsfile Corp. - December 5, 2023) - The Office of the Investor Advocate of the Securities and Exchange Commission today published its Report on Activities for the Fiscal Year 2023 to Congress.

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - December 5, 2023) - The Office of the Investor Advocate of the Securities and Exchange Commission today published its Report on Activities for the Fiscal Year 2023 to Congress.
  • The report highlights the work of the Office during the fiscal year.
  • Notable highlights from the report include:
    Empirical research findings about investors’ comprehension of registered index-linked annuities as well as policy recommendations;
    Research findings about investment advisory agreements use of mandatory arbitration clauses including suggested approaches on combating abusive use of those clauses;
    Metrics measuring the activities of the Office including the substantial uptick in investor engagement, investor submissions, and inquiries; and
    Topical discussions of private markets, cybersecurity, and equity market structure.
  • The Office of the Investor Advocate is an independent office within the SEC, created by Congress, to provide investors with a voice inside the Commission, to assist retail investors, to study investor behavior, and to support the Investor Advisory Committee of the Commission.

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Retrieved on: 
星期一, 十一月 13, 2023
Webcast, Pancreatic cancer, MK2, Safety, Therapy, Clinical trial, Patient, ACR20, Rheumatoid arthritis, ACRS, Pharmacokinetics, Ulcerative colitis, Atopic dermatitis, Topical medication, Toxic leukoencephalopathy, Osteoporosis, MTX, Pharmaceutical industry, Czech Republic

WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202).

Key Points: 
  • The primary efficacy endpoint is the proportion of patients achieving an ACR20 response following 12 weeks of treatment.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris’ ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
  • “We are deeply disappointed with the results of this trial and for patients suffering from rheumatoid arthritis.
  • Aclaris is supporting Washington University in a first-in-human investigator-initiated Phase 1a trial of ATI-2231 in patients with advanced solid tumor malignancies.

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

Retrieved on: 
星期五, 九月 29, 2023
Biotechnology, Radiology, Health, Oncology, Real, GBM, Body mass index, Effect, ASTRO, Topical medication, Survival, Skin, Meta-analysis, Radiation treatment planning, Radiation therapy, Patient, Lung, Science in newly industrialized countries, Annual general meeting, Systematic review, Neoplasm, Epigastrium, BMI, Society, Treatment, American Society for Radiation Oncology, Software, Medical imaging, Medical device, Pharmaceutical industry, Communications satellite, Glioblastoma, Dosimetry

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.
  • Results support the feasibility of TTFields therapy delivery to the lungs regardless of BMI and highlight the importance of choosing the appropriate array size for each patient.
  • “We are committed to continuous innovation, and we look forward to sharing new insights about the use of TTFields therapy with the scientific community,” said Pritesh Shah, Novocure’s Chief Growth Officer.
  • Tumor Treating Fields (TTFields) in the Real World for Newly Diagnosed Glioblastoma: A Survival Meta-analysis With Systematic Review.

GSE Services Support Topical Report for using Data Validation and Reconciliation for Measurement Uncertainty Recapture

Retrieved on: 
星期一, 九月 25, 2023
Workforce, GSE Systems, Nuclear Regulatory Commission, DVR, Engineering, NRC, Topical medication, Data validation and reconciliation, Plant, Measurement uncertainty, Safety, GSE, Renewable energy

COLUMBIA, Md., Sept. 25, 2023 /PRNewswire/ -- GSE Solutions ("GSE Systems, Inc." or "GSE") (Nasdaq: GVP), a leader in advanced engineering and workforce solutions that supports the future of clean-energy production and decarbonization initiatives for the nuclear power industry, announced that it has developed key services that support recent Topical Report, which outlines the requirements for using Data Validation and Reconciliation (DVR) for Measurement Uncertainty Recapture (MUR).

Key Points: 
  • COLUMBIA, Md., Sept. 25, 2023 /PRNewswire/ -- GSE Solutions ("GSE Systems, Inc." or "GSE") (Nasdaq: GVP), a leader in advanced engineering and workforce solutions that supports the future of clean-energy production and decarbonization initiatives for the nuclear power industry, announced that it has developed key services that support recent Topical Report, which outlines the requirements for using Data Validation and Reconciliation (DVR) for Measurement Uncertainty Recapture (MUR) .
  • In July 2023, the Nuclear Regulatory Commission (NRC) released the final safety evaluation of the Topical Report submitted for applying DVR to MUR uprates.
  • DVR is the new elite standard for optimizing plant performance in the nuclear power industry and can now be used to implement uprates of up to approximately 1.4%.
  • Then, the GSE team uses data analytics to monitor, troubleshoot, and make operational improvements that increase plant output and ensure efficient and safe operations, providing significant economic benefits to the utility.

New Enhancements and Advancements in the Companion Animal Ear Infection Treatment Market 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
星期三, 八月 23, 2023
Pharmaceutical, Health, Veterinary, Cats and Dogs, Pressure, High, Research report, Block cipher mode of operation, Labyrinthitis, Dog, COVID-19, Consumer, Research, USD, Cat, Certification, Compound annual growth rate, Otitis externa, Social impact assessment, Investment, Quinolone antibiotic, Oral, R, Vaccine, Pharmaceutical industry, Pet industry, Topical medication, Aminoglycoside, Otitis media

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.

Key Points: 
  • The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Companion Animal Ear Infection Treatment Market.
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Companion Animal Ear Infection Treatment Market?
  • What is the market share of the leading vendors in the Global Companion Animal Ear Infection Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Companion Animal Ear Infection Treatment Market?

North America Dental Anesthesia Market Analysis/Forecasts 2023-2030 - Rising Incidence of Dental Problems and Growing Demand for Cosmetic Dentistry to Fuel Growth - ResearchAndMarkets.com

Retrieved on: 
星期三, 七月 19, 2023
Pharmaceutical, Health, Surgery, Dental, Dentistry, Topical medication, AADA, USD, Hygiene, Incidence, Retirement, Local, Economic policy of the Donald Trump administration, Dental care, American Dental Association, Diagnosis, Growth, CCHS, Community health, Airline

Furthermore, an increase in dental care services coupled with a surge in the number of dental clinics, and an increase in dental care expenditure also remain promising drivers.

Key Points: 
  • Furthermore, an increase in dental care services coupled with a surge in the number of dental clinics, and an increase in dental care expenditure also remain promising drivers.
  • Moreover, an increase in the frequency of people seeking routine dental care, especially older adults, and growing demand for cosmetic dentistry are some of the major factors expected to contribute to growth over the forecast period.
  • The factors such as preventive approaches toward dental anesthesia & hygiene, growing R&D activities in dentistry, and increasing disposable income are expected to boost the market growth.
  • Based on the type segment, local dental anesthesia dominated the dental anesthesia market in terms of revenue with a market share of 64.3% in 2022.